Baxter Raises 2026 Sales And Profit Outlook, Though Adjusted EPS Falls 16% To $0.58

Third-quarter sales rose 5% to $2.98 billion, but a higher tax rate cut adjusted earnings per share from $0.69 a year earlier.

Share
Baxter Raises 2026 Sales And Profit Outlook, Though Adjusted EPS Falls 16% To $0.58

Baxter International, which makes IV solutions, infusion systems and hospital beds, raised its full-year 2026 outlook on Thursday after third-quarter sales rose 5% to $2.98 billion, with growth in every segment. Adjusted earnings per share still fell 16% to $0.58 from $0.69 a year earlier, which the company blamed on a higher effective tax rate.

Sales up, adjusted profit down

Sales grew 5% on both a reported and organic basis, the company said in its 8-K and earnings release. U.S. sales of about $1.6 billion rose 3% reported and 5% organic. International sales of about $1.4 billion rose 7% reported and 6% organic.

Standard-accounting net income was $298 million, or $0.57 per diluted share. Adjusted earnings per share were $0.58, down 16%.

CEO Andrew Hider said Baxter delivered "a strong third quarter, with growth across all segments and divisions globally."

Infusion gains, weaker injectables

Medical Products & Therapies sales rose 6% to about $2.1 billion. Infusion Systems, Drug Compounding and IV Solutions drove the gains, and Advanced Surgery demand also helped, while lower Injectables sales partly offset them.

Healthcare Systems & Technologies rose 4% to about $806 million, led by Care & Connectivity Solutions, with growth in Global Surgical Solutions and Patient Support Systems. Front Line Care also grew.

Baxter sells hospital, nursing home, dialysis and home-care customers a wide range of products through its own sales force, distributors and wholesalers.

Higher guidance and debt paydown

The company now expects:

  • Reported sales growth of 4% to 5%, up from 3% to 4%.
  • Organic sales growth of 3% to 4%, up from 2% to 3%.
  • Adjusted earnings per share of $2.05 to $2.15, up from $1.95 to $2.15.

Free cash flow was $448 million in the quarter and $705 million for the first nine months. Baxter also completed a $600 million cash tender offer that retired $864 million of debt, which it said speeds deleveraging while supporting its investment-grade credit objectives.

The board declared a quarterly dividend of $0.01 per share, payable January 4, 2027, to holders of record on November 27, 2026.

Baxter's next scheduled investor event is the J.P. Morgan Healthcare Conference on January 11-13, 2027.

Sources

More on Baxter International

All Baxter International (BAX) coverage →